Hepatitis B
hepatitis-b · society: AASLD
← back to Gastroenterology & Hepatology
Summary
AASLD 2018 guidance updates the 2016 Hepatitis B Treatment Guidelines, adding tenofovir alafenamide (TAF) as a preferred first-line NA and elevating tenofovir disoproxil fumarate (TDF) to preferred therapy for prevention of mother-to-child transmission. It covers screening, counseling, prevention, virological assays, monitoring of untreated patients, and management in special populations (HCV/HDV/HIV coinfection, immunosuppression, acute HBV, pregnancy, cirrhosis, transplant recipients, children). Preferred antivirals remain peg-IFN, entecavir, TDF, and TAF; TAF offers improved renal and bone safety vs TDF with comparable efficacy.
Current guideline: AASLD 2018 Hepatitis B Guidance · 
download Anki sub-deck
Versions
- 2018 · AASLD — AASLD 2018 Hepatitis B Guidance